Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Serotypes

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    219 result(s) found for: Serotypes. Displaying page 1 of 11.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-001716-19 Sponsor Protocol Number: CYD15 Start Date*: 2014-05-26
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America
    Medical condition: Prevention of symptomatic dengue disease
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001708-24 Sponsor Protocol Number: CYD14 Start Date*: 2014-05-26
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia
    Medical condition: Prevention of symptomatic dengue disease
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2023-000027-36 Sponsor Protocol Number: DEN-303 Start Date*: 2023-02-03
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: A Phase 3, Follow-Up Trial to Evaluate Long-Term Safety and Antibody Persistence, and the Impact of a Booster Dose of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescents and Adults in Are...
    Medical condition: Dengue fever
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10012312 Dengue fever virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2018-003068-29 Sponsor Protocol Number: P170934J Start Date*: 2018-11-07
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Evaluation of immunological response following a revaccination with PPS23 boosted or not by PCV13 in splenectomised patients (SPLENEVAC-2)
    Medical condition: Asplenic patients at risk for invasive pneumococcal diseases
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10041642 Splenectomy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004158-32 Sponsor Protocol Number: 6096A1-3016 Start Date*: 2015-04-09
    Sponsor Name:Wyeth Pharmaceuticals, Inc. Acting through its division Wyeth Research, a Pfizer Company
    Full Title: PILOT: Characterization of the Prevnar Infant Long-Term Immune Response Versus a Prevnar-Naïve Cohort
    Medical condition: Pneumococcal infection
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-003308-11 Sponsor Protocol Number: B7471014 Start Date*: 2022-09-07
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, SINGLE-ARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE
    Medical condition: Pneumococcal Disease
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-005273-27 Sponsor Protocol Number: VAC52416BAC3001 Start Date*: 2021-09-07
    Sponsor Name:Janssen Vaccines & Prevention B.V
    Full Title: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal P...
    Medical condition: Invasive Extraintestinal Pathogenic Escherichia coli Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10052238 Escherichia urinary tract infection PT
    20.0 10021881 - Infections and infestations 10015295 Escherichia infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) IT (Prematurely Ended) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023384-18 Sponsor Protocol Number: 730901 Start Date*: 2011-03-14
    Sponsor Name:Baxter Innovations GmbH
    Full Title: Randomized, double-blind, phase I/II clinical study to investigate the safety and immunogenicity of a multivalent recombinant OspA Lyme Borreliosis vaccine (mv rOspA LB Vaccine) in healthy subjects...
    Medical condition: -) To obtain safety and immunogenicity data of different dose levels of a mv rOspA LB Vaccine with and without adjuvant in seronegative healthy volunteers aged 18 to 70 years. The outcome shall pro...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004862 10067559 Lyme borreliosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001118-40 Sponsor Protocol Number: NL69183.xxx.19 Start Date*: 2019-08-22
    Sponsor Name:Department of Pulmonology
    Full Title: Response to pneumococcal polysaccharide vaccination in healthy adults
    Medical condition: immunodeficiency
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004178-40 Sponsor Protocol Number: B1841008 Start Date*: 2015-04-03
    Sponsor Name:Pfizer, Inc.
    Full Title: A Phase 4, Open-label Trial to Assess the Safety, Tolerability, and Immunogenicity of Prevenar in Older Infants and Young Children in China Who Are Naive to Previous Pneumococcal Vaccination
    Medical condition: Pneumococcal Infections
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-001458-24 Sponsor Protocol Number: VAC-264 Start Date*: 2012-09-03
    Sponsor Name:RIVM
    Full Title: Cross-sectional surveillance study on pneumococcal serotypes and other pathogens in nasopharyngeal samples from infants and parents performed 6.5 years after introduction of pneumococcal vaccinatio...
    Medical condition: The study investigates the presence of nasopharyngeal vaccine- and non-vaccine pneumococcal serotypes in 11- and 24-month-old infants and parents, 6.5 years after implementation of a pneumococcal v...
    Disease:
    Population Age: Infants and toddlers, Children, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-000265-41 Sponsor Protocol Number: V116-04 Start Date*: 2022-08-29
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3 Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults 18 to 49 Years of Age
    Medical condition: Pneumococcal disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10035644 Pneumococcal infection NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) AT (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000264-15 Sponsor Protocol Number: V260-029 Start Date*: 2017-03-07
    Sponsor Name:Banyu Pharmaceutical Co., Ltd. a subsidiary of Merck & Co.,Inc, Kenilworth, New Jersey, USA
    Full Title: A phase III randomized, placebo-controlled clinical trial to study the efficacy and safety of V260 in healthy infants in Japan
    Medical condition: Prevention of Rotavirus Gastroenteritis Caused by Serotypes G1, G2, G3, G4, and G-Serotypes Associated With P1A [8] (e.g., G9) in Infants
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004862 10039232 Rotavirus gastroenteritis LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005337-45 Sponsor Protocol Number: PNA19 Start Date*: 2015-12-07
    Sponsor Name:SANOFI PASTEUR SA
    Full Title: Immunogenicity and Safety of a Booster Dose of Polysaccharide Pneumococcal vaccine (Pneumo 23®) in 12 to 18 Months-Old Children Primed with Three Doses of Pneumococcal Conjugate Vaccine (Prevnar®) ...
    Medical condition: Healthy volunteers: prevention of invasive disease caused by S pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F and prevention of otitis media caused by S pneumoniae serotypes 4, 6B, 9V, 14, ...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-000083-17 Sponsor Protocol Number: NVI-245 Start Date*: 2008-03-19
    Sponsor Name:Nederlands Vaccin Instituut
    Full Title: Nasopharyngeal pneumococcal colonization data in infants at the age of 12, 18 and 24 months
    Medical condition: Pneumococcal carriership in children having previously received Prevenar vaccination (7-valent pneumococcal conjugate vaccine) according to the 3+1 vaccination schedule used in the Dutch National I...
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2022-001146-38 Sponsor Protocol Number: B7471016 Start Date*: 2022-09-27
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY UNBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY JAPANESE INFANTS
    Medical condition: Pneumococcal disease
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-003455-33 Sponsor Protocol Number: INV-DEN-203 Start Date*: 2022-12-21
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: A Double-Blind, Randomized, Placebo-Controlled, Age Descending and Expansion Phase 2 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteer...
    Medical condition: Dengue Fever
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10012312 Dengue fever virus infection LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-012642-22 Sponsor Protocol Number: 0887x1-20003 Start Date*: 2009-12-18
    Sponsor Name:Swedish CLL-group
    Full Title: A Randomized Phase III Trial to Determine Whether Conjugated Pneumococcal Vaccine Can Improve the Immune Responsiveness Compared to Polyclonal Pneumococcal Vaccine in Patients With Untreated Chroni...
    Medical condition: The purpose of the study is to determine wheter patients with chronic lymphocytic leukaemia (CLL) will benefit from vaccination with conjugated pneumococcal vaccine compared to conventional 23-vale...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005102-30 Sponsor Protocol Number: OVG2011/05 Start Date*: 2011-12-08
    Sponsor Name:University of Oxford
    Full Title: A phase III randomised, open label clinical trial evaluating the immunogenicity of a 10-valent pneumococcal conjugate vaccine booster compared to the standard 13-valent pneumococcal conjugate vacci...
    Medical condition: The study will include healthy children who have already been vaccinated with 2 doses of Prevenar 13 according to the UK routine immunisation schedule at 2 and 4 months of age. Both vaccines used i...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-005134-29 Sponsor Protocol Number: B4671004 Start Date*: 2020-03-30
    Sponsor Name:Pfizer Inc
    Full Title: A PHASE 4, RANDOMIZED, OPEN-LABEL TRIAL TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 13- VALENT PNEUMOCOCCAL CONJUGATE VACCINE FORMULATED IN MULTIDOSE VIALS WHEN GIVEN WITH ROUTINE P...
    Medical condition: Infections caused by Streptococcus Pneumoniae
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 08:59:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA